20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T2072 | BET bromodomain inhibitor | Epigenetic Reader Domain | |
BET bromodomain inhibitor is a potent BET inhibitor. | |||
T39998 | BET bromodomain inhibitor 1 | ||
BET bromodomain inhibitor 1 is an orally active, selective inhibitor of bromodomain and extra-terminal (BET) proteins. It specifically inhibits BRD4 with an IC50 of 2.6 nM. Additionally, BET bromodomain inhibitor 1 demon... | |||
T2120 | I-BET151 | GSK1210151A | Epigenetic Reader Domain |
I-BET151 (GSK1210151A) (GSK1210151A) is a specific BET inhibitor for BRD2/3/4 (IC50: 0.5/0.25/0.79 μM, in cell-free assays). | |||
T79084 | BET bromodomain inhibitor 3 | Epigenetic Reader Domain | |
BET Bromodomain Inhibitor 3 is a BET bromodomain inhibitor with an inhibitory Ki value of >40 µM against BrdT. It is utilized in research related to contraception, cancer, and heart disease [1]. | |||
T62655 | BET bromodomain inhibitor 2 | ||
BET bromodomain inhibitor 2 is a potent inhibitor of the BET-type bromodomain (IC50: 14.1 μM). | |||
T6859 | I-BRD9 | GSK602 | Epigenetic Reader Domain |
I-BRD9 (GSK602) is the first selective cellular inhibitor for BRD9 with pIC50 of 7.3. | |||
T8495 | Alobresib | Vorolanib,GS-5829 | Epigenetic Reader Domain |
Alobresib (Vorolanib) is an inhibitor of BET bromodomain,is an antineoplastic drug candidate. | |||
T2442 | CPI203 | CPI 203,CPI-203 | Epigenetic Reader Domain |
CPI203 (CPI 203) is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4). | |||
T5362 | Y06036 | Epigenetic Reader Domain | |
Y06036, a potent and selective BET inhibitor, can bind to the BRD4(1) bromodomain (Kd: 82 nM). | |||
T17311 | (+)-JQ1 PA | Epigenetic Reader Domain | |
(+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal (BET) inhibitor JQ1(IC50 of 10.4 nM). | |||
T8658 | NEO2734 | EP31670 | Epigenetic Reader Domain , Histone Acetyltransferase |
NEO2734 (EP31670) is an orally active and selective inhibitor of p300/CBP and BET bromodomain(IC50 of <30 nM for both p300/CBP and BET bromodomains). | |||
T2480 | Apabetalone | RVX-208,RVX000222 | Epigenetic Reader Domain , HIV Protease |
Apabetalone (RVX000222) , an effective BET bromodomain inhibitor, has been investigated for the treatment of diabetes, atherosclerosis, and coronary artery disease. | |||
T6026 | CPI-203 | CPI 203,CPI203 | Apoptosis , Epigenetic Reader Domain |
CPI-203 is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4). | |||
T6222 | PFI-1 | PF-6405761,PFI 1,PFI1 | Apoptosis , Epigenetic Reader Domain , Autophagy |
PFI-1 (PF-6405761), a specific BET (bromodomain-containing protein) inhibitor for BRD4, is with the IC50 of 0.22 μM in a cell-free assay. | |||
T12338 | OXFBD04 | Epigenetic Reader Domain | |
OXFBD04 is a potent and selective BRD4 inhibitor (IC50= 166 nM). OXFBD04 is a potent BET bromodomain ligand and exhibits additional modest affinity for the CREBBP bromodomain. OXFBD04 exhibits anti-cancer activity. | |||
T6032 | Birabresib | OTX-015,OTX015 (MK 8628/Birabresib),MK-8628 | Epigenetic Reader Domain |
Birabresib (MK-8628) is a synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity. | |||
T4697 | ABBV-744 | ABBV744 | Epigenetic Reader Domain , HIV Protease |
ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2/3/4. It is used in the research on inflammatory diseases, cancer, and AIDS. | |||
T19618 | (R)-(-)-JQ1 Enantiomer | Epigenetic Reader Domain | |
(R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 is a BET bromodomain inhibitor, acting on BRD4(1/2)(IC50 of 77 nM/33 nM in a cell-free assay) | |||
T3504 | AZD5153 6-Hydroxy-2-naphthoic acid | AZD5153,AZD-5153 HNT salt | Epigenetic Reader Domain |
AZD5153 6-Hydroxy-2-naphthoic acid (AZD5153) is a potent triazolopyridazine-based Bromodomain (BRD4) and Extraterminal (BET) inhibitor used in cancer treatments. | |||
T19935 | XD14 | Epigenetic Reader Domain | |
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively). |